Abbott Laboratories (ABT) has an enviable problem: It can’t produce enough rapid at-home COVID-19 antigen tests to keep up with demand.
The company had previously warned that there would be a shortage of tests, though they are not the result of the supply chain issues many companies are facing.
In a statement, Abbott explained that the company had started to reduce production when demand waned earlier this year.
But following the surge of the Delta variant in recent months, which resulted in a…
Source link
